Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors

Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF1 an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 1996-10, Vol.88 (19), p.1399-1404
Hauptverfasser: Ding, Ivan, Huang, Kundi, Snyder, Matthew L., Cook, John, Zhang, Lurong, Wersto, Nancy, Okunieff, Paul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1404
container_issue 19
container_start_page 1399
container_title JNCI : Journal of the National Cancer Institute
container_volume 88
creator Ding, Ivan
Huang, Kundi
Snyder, Matthew L.
Cook, John
Zhang, Lurong
Wersto, Nancy
Okunieff, Paul
description Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF1 and FGF2, respectively) has recently been demonstrated after whole-body irradiation of C3H/HeN mice. Purpose: Our purpose was to determine whether myeloprotective doses of those growth factors also protect malignant tumors. Methods: First, we investigated the effects of exogenous FGF1 or FGF2 (FGF1/2) administration (treatment group receiving two intravenous injections of 3 μg FGF1/2 per mouse 24 hours and 4 hours before local irradiation of right hind leg and control group receiving two intravenous injections of 0.1 mL of saline) on growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma [SCC-VII] and two sarcomas [KHT and Rif-1]), all of which were grown in C3H/HeN mice. We then evaluated the effect of FGF1/2 on tumor cell proliferation, cell cycle distribution, and pulmonary metastatic frequency in the mice. Specifically, survival studies were performed in mice treated with 0, 6, 6.5, 7.5, 8.5, 9, or 10 Gy whole-body irradiation with or without FGF2 (n = 250). Rif-1 (n = 40), KHT (n = 40), and SCC-VII (n = 40) tumors were implanted in the hind leg of mice, and mice were treated with FGF2 or saline when their tumor-bearing thighs were 9 mm in diameter. In separate experiments (treatment group receiving two injections of 3 μg each of FGF2 [6 μg total] either intravenously or intratumorally 24 hours and 4 hours before local tumor irradiation and control group receiving 0.1 mL saline), tumor growth was followed, and mice were killed to count lung metastases and measure tumor proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine labeling at various times thereafter (three to eight mice per group). Tumor growth curves of untreated and irradiated tumors were determined with and without intravenous or intratumoral FGF1/2 in SCC-VII tumors (n = 120). Radiation doses to the tumor-bearing leg were 15 and 30 Gy for SCC-VII, 30 Gy for Rif-1, and 15 Gy for KHT. From each experiment, the mean (±1 standard error) was calculated from data obtained from three to 20 mice. Statistical tests used included two-tailed Student's t test, the chi-squared test, and Fisher's exact test. All P values represent two-tailed tests of statistical
doi_str_mv 10.1093/jnci/88.19.1399
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_235595580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10309021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-1e89517e017612d9663607b696d23f98855e0720a24cf2389b180da9ad2a4ab13</originalsourceid><addsrcrecordid>eNo9kEtPAyEYRYnRaK2uXZkQ43ZaHsMAS1-txjY-otG4IcwME6ntoEDV_ntpWssGwj2cj1wAjjDqYSRpf9JWti9ED8seplJugQ7OC5QRjNg26CBEeCYEz_fAfggTlJYk-S7YFYJwhEUHvD_NZ87DoXc_8R3qtoari0ddWxdMG2y03zYuoG3h2FYGDu23SceFmbpP76KpUm7gZWIDdA0c2NK7cqpD_HcOdBWdDwdgp9HTYA7Xexc8D66eLq6z0d3w5uJslFU54THDRkiGuUGYF5jUsihogXhZyKImtJFCMGYQJ0iTvGoIFbLEAtVa6proXJeYdsHJypt-9zU3IaqJm_s2jVSEMiYZEyhB_RVUeReCN4369Ham_UJhpJa9qmWvSgiFpVr2ml4cr7XzcmbqDb8uMuWn61yHSk8br5MgbDDCEGP5UpOtMBui-d3E2n-oglPO1PXrm3p7eRiMz8f36pb-AVXxkAk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>235595580</pqid></control><display><type>article</type><title>Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ding, Ivan ; Huang, Kundi ; Snyder, Matthew L. ; Cook, John ; Zhang, Lurong ; Wersto, Nancy ; Okunieff, Paul</creator><creatorcontrib>Ding, Ivan ; Huang, Kundi ; Snyder, Matthew L. ; Cook, John ; Zhang, Lurong ; Wersto, Nancy ; Okunieff, Paul</creatorcontrib><description>Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF1 and FGF2, respectively) has recently been demonstrated after whole-body irradiation of C3H/HeN mice. Purpose: Our purpose was to determine whether myeloprotective doses of those growth factors also protect malignant tumors. Methods: First, we investigated the effects of exogenous FGF1 or FGF2 (FGF1/2) administration (treatment group receiving two intravenous injections of 3 μg FGF1/2 per mouse 24 hours and 4 hours before local irradiation of right hind leg and control group receiving two intravenous injections of 0.1 mL of saline) on growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma [SCC-VII] and two sarcomas [KHT and Rif-1]), all of which were grown in C3H/HeN mice. We then evaluated the effect of FGF1/2 on tumor cell proliferation, cell cycle distribution, and pulmonary metastatic frequency in the mice. Specifically, survival studies were performed in mice treated with 0, 6, 6.5, 7.5, 8.5, 9, or 10 Gy whole-body irradiation with or without FGF2 (n = 250). Rif-1 (n = 40), KHT (n = 40), and SCC-VII (n = 40) tumors were implanted in the hind leg of mice, and mice were treated with FGF2 or saline when their tumor-bearing thighs were 9 mm in diameter. In separate experiments (treatment group receiving two injections of 3 μg each of FGF2 [6 μg total] either intravenously or intratumorally 24 hours and 4 hours before local tumor irradiation and control group receiving 0.1 mL saline), tumor growth was followed, and mice were killed to count lung metastases and measure tumor proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine labeling at various times thereafter (three to eight mice per group). Tumor growth curves of untreated and irradiated tumors were determined with and without intravenous or intratumoral FGF1/2 in SCC-VII tumors (n = 120). Radiation doses to the tumor-bearing leg were 15 and 30 Gy for SCC-VII, 30 Gy for Rif-1, and 15 Gy for KHT. From each experiment, the mean (±1 standard error) was calculated from data obtained from three to 20 mice. Statistical tests used included two-tailed Student's t test, the chi-squared test, and Fisher's exact test. All P values represent two-tailed tests of statistical significance. Results: There was no statistically significant difference in tumor growth rate between FGF2-treated and saline-treated mice when FGF2 was administered intravenously at doses and schedules found to be optimally myeloprotective in whole-body irradiation experiments. Intravenous administration of FGF2 did not induce lung metastases, and it did not augment the S-phase fraction of tumor cells. Likewise, there was no evidence of enhanced cell proliferation as measured by PCNA-labeling index. Intratumoral injection of FGF1/2 did increase the size of SCC-VII tumors (P&lt;.05 [Student's t test] at 3 days after treatment); however, the radiation response after intratumoral injection of growth factor was not compromised. Conclusion: Low intravenous doses of FGF1 or FGF2 appear to protect bone marrow from the toxic effects of radiation without increasing the rates of tumor growth or metastases or decreasing the radiosensitivity of tumors.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/88.19.1399</identifier><identifier>PMID: 8827018</identifier><identifier>CODEN: JNCIEQ</identifier><language>eng</language><publisher>Cary, NC: Oxford University Press</publisher><subject>Animals ; Biological and medical sciences ; Bone marrow ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - secondary ; Cell Division - drug effects ; Cell Division - radiation effects ; Fibroblast Growth Factor 2 - pharmacology ; Immunohistochemistry - methods ; Injections, Intravenous ; Lung Neoplasms - prevention &amp; control ; Lung Neoplasms - secondary ; Medical research ; Medical sciences ; Mice ; Mice, Inbred C3H ; Neoplasm Transplantation ; Proliferating Cell Nuclear Antigen - analysis ; Radiation therapy and radiosensitizing agent ; Radiation-Protective Agents - pharmacology ; Receptors, Fibroblast Growth Factor - analysis ; Recombinant Proteins - pharmacology ; Rodents ; Sarcoma, Experimental - radiotherapy ; Sarcoma, Experimental - secondary ; Time Factors ; Treatment with physical agents ; Treatment. General aspects ; Tumors</subject><ispartof>JNCI : Journal of the National Cancer Institute, 1996-10, Vol.88 (19), p.1399-1404</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 2, 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-1e89517e017612d9663607b696d23f98855e0720a24cf2389b180da9ad2a4ab13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2505549$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8827018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ding, Ivan</creatorcontrib><creatorcontrib>Huang, Kundi</creatorcontrib><creatorcontrib>Snyder, Matthew L.</creatorcontrib><creatorcontrib>Cook, John</creatorcontrib><creatorcontrib>Zhang, Lurong</creatorcontrib><creatorcontrib>Wersto, Nancy</creatorcontrib><creatorcontrib>Okunieff, Paul</creatorcontrib><title>Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF1 and FGF2, respectively) has recently been demonstrated after whole-body irradiation of C3H/HeN mice. Purpose: Our purpose was to determine whether myeloprotective doses of those growth factors also protect malignant tumors. Methods: First, we investigated the effects of exogenous FGF1 or FGF2 (FGF1/2) administration (treatment group receiving two intravenous injections of 3 μg FGF1/2 per mouse 24 hours and 4 hours before local irradiation of right hind leg and control group receiving two intravenous injections of 0.1 mL of saline) on growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma [SCC-VII] and two sarcomas [KHT and Rif-1]), all of which were grown in C3H/HeN mice. We then evaluated the effect of FGF1/2 on tumor cell proliferation, cell cycle distribution, and pulmonary metastatic frequency in the mice. Specifically, survival studies were performed in mice treated with 0, 6, 6.5, 7.5, 8.5, 9, or 10 Gy whole-body irradiation with or without FGF2 (n = 250). Rif-1 (n = 40), KHT (n = 40), and SCC-VII (n = 40) tumors were implanted in the hind leg of mice, and mice were treated with FGF2 or saline when their tumor-bearing thighs were 9 mm in diameter. In separate experiments (treatment group receiving two injections of 3 μg each of FGF2 [6 μg total] either intravenously or intratumorally 24 hours and 4 hours before local tumor irradiation and control group receiving 0.1 mL saline), tumor growth was followed, and mice were killed to count lung metastases and measure tumor proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine labeling at various times thereafter (three to eight mice per group). Tumor growth curves of untreated and irradiated tumors were determined with and without intravenous or intratumoral FGF1/2 in SCC-VII tumors (n = 120). Radiation doses to the tumor-bearing leg were 15 and 30 Gy for SCC-VII, 30 Gy for Rif-1, and 15 Gy for KHT. From each experiment, the mean (±1 standard error) was calculated from data obtained from three to 20 mice. Statistical tests used included two-tailed Student's t test, the chi-squared test, and Fisher's exact test. All P values represent two-tailed tests of statistical significance. Results: There was no statistically significant difference in tumor growth rate between FGF2-treated and saline-treated mice when FGF2 was administered intravenously at doses and schedules found to be optimally myeloprotective in whole-body irradiation experiments. Intravenous administration of FGF2 did not induce lung metastases, and it did not augment the S-phase fraction of tumor cells. Likewise, there was no evidence of enhanced cell proliferation as measured by PCNA-labeling index. Intratumoral injection of FGF1/2 did increase the size of SCC-VII tumors (P&lt;.05 [Student's t test] at 3 days after treatment); however, the radiation response after intratumoral injection of growth factor was not compromised. Conclusion: Low intravenous doses of FGF1 or FGF2 appear to protect bone marrow from the toxic effects of radiation without increasing the rates of tumor growth or metastases or decreasing the radiosensitivity of tumors.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Cell Division - drug effects</subject><subject>Cell Division - radiation effects</subject><subject>Fibroblast Growth Factor 2 - pharmacology</subject><subject>Immunohistochemistry - methods</subject><subject>Injections, Intravenous</subject><subject>Lung Neoplasms - prevention &amp; control</subject><subject>Lung Neoplasms - secondary</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C3H</subject><subject>Neoplasm Transplantation</subject><subject>Proliferating Cell Nuclear Antigen - analysis</subject><subject>Radiation therapy and radiosensitizing agent</subject><subject>Radiation-Protective Agents - pharmacology</subject><subject>Receptors, Fibroblast Growth Factor - analysis</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Rodents</subject><subject>Sarcoma, Experimental - radiotherapy</subject><subject>Sarcoma, Experimental - secondary</subject><subject>Time Factors</subject><subject>Treatment with physical agents</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtPAyEYRYnRaK2uXZkQ43ZaHsMAS1-txjY-otG4IcwME6ntoEDV_ntpWssGwj2cj1wAjjDqYSRpf9JWti9ED8seplJugQ7OC5QRjNg26CBEeCYEz_fAfggTlJYk-S7YFYJwhEUHvD_NZ87DoXc_8R3qtoari0ddWxdMG2y03zYuoG3h2FYGDu23SceFmbpP76KpUm7gZWIDdA0c2NK7cqpD_HcOdBWdDwdgp9HTYA7Xexc8D66eLq6z0d3w5uJslFU54THDRkiGuUGYF5jUsihogXhZyKImtJFCMGYQJ0iTvGoIFbLEAtVa6proXJeYdsHJypt-9zU3IaqJm_s2jVSEMiYZEyhB_RVUeReCN4369Ham_UJhpJa9qmWvSgiFpVr2ml4cr7XzcmbqDb8uMuWn61yHSk8br5MgbDDCEGP5UpOtMBui-d3E2n-oglPO1PXrm3p7eRiMz8f36pb-AVXxkAk</recordid><startdate>19961002</startdate><enddate>19961002</enddate><creator>Ding, Ivan</creator><creator>Huang, Kundi</creator><creator>Snyder, Matthew L.</creator><creator>Cook, John</creator><creator>Zhang, Lurong</creator><creator>Wersto, Nancy</creator><creator>Okunieff, Paul</creator><general>Oxford University Press</general><general>Superintendent of Documents</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>19961002</creationdate><title>Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors</title><author>Ding, Ivan ; Huang, Kundi ; Snyder, Matthew L. ; Cook, John ; Zhang, Lurong ; Wersto, Nancy ; Okunieff, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-1e89517e017612d9663607b696d23f98855e0720a24cf2389b180da9ad2a4ab13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Cell Division - drug effects</topic><topic>Cell Division - radiation effects</topic><topic>Fibroblast Growth Factor 2 - pharmacology</topic><topic>Immunohistochemistry - methods</topic><topic>Injections, Intravenous</topic><topic>Lung Neoplasms - prevention &amp; control</topic><topic>Lung Neoplasms - secondary</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C3H</topic><topic>Neoplasm Transplantation</topic><topic>Proliferating Cell Nuclear Antigen - analysis</topic><topic>Radiation therapy and radiosensitizing agent</topic><topic>Radiation-Protective Agents - pharmacology</topic><topic>Receptors, Fibroblast Growth Factor - analysis</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Rodents</topic><topic>Sarcoma, Experimental - radiotherapy</topic><topic>Sarcoma, Experimental - secondary</topic><topic>Time Factors</topic><topic>Treatment with physical agents</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ding, Ivan</creatorcontrib><creatorcontrib>Huang, Kundi</creatorcontrib><creatorcontrib>Snyder, Matthew L.</creatorcontrib><creatorcontrib>Cook, John</creatorcontrib><creatorcontrib>Zhang, Lurong</creatorcontrib><creatorcontrib>Wersto, Nancy</creatorcontrib><creatorcontrib>Okunieff, Paul</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ding, Ivan</au><au>Huang, Kundi</au><au>Snyder, Matthew L.</au><au>Cook, John</au><au>Zhang, Lurong</au><au>Wersto, Nancy</au><au>Okunieff, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>1996-10-02</date><risdate>1996</risdate><volume>88</volume><issue>19</issue><spage>1399</spage><epage>1404</epage><pages>1399-1404</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><coden>JNCIEQ</coden><abstract>Background: Radiation at doses high enough to cure cancer also frequently destroys normal tissue. Development of agents that protect normal tissue without also protecting diseased tissue has been difficult. In vivo radioprotection of bone marrow by acidic and basic fibroblast growth factors (FGF1 and FGF2, respectively) has recently been demonstrated after whole-body irradiation of C3H/HeN mice. Purpose: Our purpose was to determine whether myeloprotective doses of those growth factors also protect malignant tumors. Methods: First, we investigated the effects of exogenous FGF1 or FGF2 (FGF1/2) administration (treatment group receiving two intravenous injections of 3 μg FGF1/2 per mouse 24 hours and 4 hours before local irradiation of right hind leg and control group receiving two intravenous injections of 0.1 mL of saline) on growth and radiosensitivity of three transplantable murine tumors (one squamous cell carcinoma [SCC-VII] and two sarcomas [KHT and Rif-1]), all of which were grown in C3H/HeN mice. We then evaluated the effect of FGF1/2 on tumor cell proliferation, cell cycle distribution, and pulmonary metastatic frequency in the mice. Specifically, survival studies were performed in mice treated with 0, 6, 6.5, 7.5, 8.5, 9, or 10 Gy whole-body irradiation with or without FGF2 (n = 250). Rif-1 (n = 40), KHT (n = 40), and SCC-VII (n = 40) tumors were implanted in the hind leg of mice, and mice were treated with FGF2 or saline when their tumor-bearing thighs were 9 mm in diameter. In separate experiments (treatment group receiving two injections of 3 μg each of FGF2 [6 μg total] either intravenously or intratumorally 24 hours and 4 hours before local tumor irradiation and control group receiving 0.1 mL saline), tumor growth was followed, and mice were killed to count lung metastases and measure tumor proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine labeling at various times thereafter (three to eight mice per group). Tumor growth curves of untreated and irradiated tumors were determined with and without intravenous or intratumoral FGF1/2 in SCC-VII tumors (n = 120). Radiation doses to the tumor-bearing leg were 15 and 30 Gy for SCC-VII, 30 Gy for Rif-1, and 15 Gy for KHT. From each experiment, the mean (±1 standard error) was calculated from data obtained from three to 20 mice. Statistical tests used included two-tailed Student's t test, the chi-squared test, and Fisher's exact test. All P values represent two-tailed tests of statistical significance. Results: There was no statistically significant difference in tumor growth rate between FGF2-treated and saline-treated mice when FGF2 was administered intravenously at doses and schedules found to be optimally myeloprotective in whole-body irradiation experiments. Intravenous administration of FGF2 did not induce lung metastases, and it did not augment the S-phase fraction of tumor cells. Likewise, there was no evidence of enhanced cell proliferation as measured by PCNA-labeling index. Intratumoral injection of FGF1/2 did increase the size of SCC-VII tumors (P&lt;.05 [Student's t test] at 3 days after treatment); however, the radiation response after intratumoral injection of growth factor was not compromised. Conclusion: Low intravenous doses of FGF1 or FGF2 appear to protect bone marrow from the toxic effects of radiation without increasing the rates of tumor growth or metastases or decreasing the radiosensitivity of tumors.</abstract><cop>Cary, NC</cop><pub>Oxford University Press</pub><pmid>8827018</pmid><doi>10.1093/jnci/88.19.1399</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8874
ispartof JNCI : Journal of the National Cancer Institute, 1996-10, Vol.88 (19), p.1399-1404
issn 0027-8874
1460-2105
language eng
recordid cdi_proquest_journals_235595580
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Animals
Biological and medical sciences
Bone marrow
Carcinoma, Squamous Cell - radiotherapy
Carcinoma, Squamous Cell - secondary
Cell Division - drug effects
Cell Division - radiation effects
Fibroblast Growth Factor 2 - pharmacology
Immunohistochemistry - methods
Injections, Intravenous
Lung Neoplasms - prevention & control
Lung Neoplasms - secondary
Medical research
Medical sciences
Mice
Mice, Inbred C3H
Neoplasm Transplantation
Proliferating Cell Nuclear Antigen - analysis
Radiation therapy and radiosensitizing agent
Radiation-Protective Agents - pharmacology
Receptors, Fibroblast Growth Factor - analysis
Recombinant Proteins - pharmacology
Rodents
Sarcoma, Experimental - radiotherapy
Sarcoma, Experimental - secondary
Time Factors
Treatment with physical agents
Treatment. General aspects
Tumors
title Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A15%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20Growth%20and%20Tumor%20Radiosensitivity%20in%20Mice%20Given%20Myeloprotective%20Doses%20of%20Fibroblast%20Growth%20Factors&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Ding,%20Ivan&rft.date=1996-10-02&rft.volume=88&rft.issue=19&rft.spage=1399&rft.epage=1404&rft.pages=1399-1404&rft.issn=0027-8874&rft.eissn=1460-2105&rft.coden=JNCIEQ&rft_id=info:doi/10.1093/jnci/88.19.1399&rft_dat=%3Cproquest_cross%3E10309021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=235595580&rft_id=info:pmid/8827018&rfr_iscdi=true